title: Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.
abstract: Severe forms of hypertension are characterized by high blood pressure combined with end organ damage. Through the development and refinement of a transgenic rat model of malignant hypertension incorporating the mouse renin gene, we previously identified a quantitative trait locus on chromosome 10, which affects malignant hypertension severity and morbidity. We next generated an inducible malignant hypertensive model where the timing, severity, and duration of hypertension was placed under the control of the researcher, allowing development of and recovery from end organ damage to be investigated. We have now generated novel consomic Lewis and Fischer rat strains with inducible hypertension and additional strains that are reciprocally congenic for the refined chromosome 10 quantitative trait locus. We have captured a modifier of end organ damage within the congenic region and, using a range of bioinformatic, biochemical and molecular biological techniques, have identified angiotensin-converting enzyme as the modifier of hypertension-induced tissue microvascular injury. Reciprocal differences between angiotensin-converting enzyme and the anti-inflammatory tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro in the kidney, a tissue susceptible to end organ damage, suggest a mechanism for the amelioration of hypertension-dependent damage.
authors.affiliation: Molecular Physiology Laboratory, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Liu
authors.forename: Christopher O C
authors.initials: CO
authors.lastname: Bellamy
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Bailey
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Mullins
authors.forename: Donald R
authors.initials: DR
authors.lastname: Dunbar
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kenyon
authors.forename: Gillian
authors.initials: G
authors.lastname: Brooker
authors.forename: Surasak
authors.initials: S
authors.lastname: Kantachuvesiri
authors.forename: Klio
authors.initials: K
authors.lastname: Maratou
authors.forename: Ali
authors.initials: A
authors.lastname: Ashek
authors.forename: Allan F
authors.initials: AF
authors.lastname: Clark
authors.forename: Stewart
authors.initials: S
authors.lastname: Fleming
authors.forename: John J
authors.initials: JJ
authors.lastname: Mullins
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001158:Arteries / Q000473:pathology; D002879:Chromosomes, Human, Pair 10; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000473:pathology*; D006974:Hypertension, Malignant / Q000473:pathology* / Q000517:prevention & control; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D051379:Mice; D008833:Microcirculation; D010179:Pancreas / Q000473:pathology; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism* / Q000627:therapeutic use; D040641:Quantitative Trait Loci; D051381:Rats; D012079:Renal Circulation; D012083:Renin / Q000235:genetics
chemical_list: C473112:Ren2 protein, mouse; D007703:Peptidyl-Dipeptidase A; D012083:Renin